BioCentury
ARTICLE | Company News

Dara BioSciences, Mission Pharmacal sales and marketing update

November 4, 2013 8:00 AM UTC

Mission granted Dara exclusive commercialization rights in the U.S. to three marketed drugs - Ferralet for anemia, Binosto alendronate for osteoporosis and Aquoral for xerostomia. Additionally, Dara entered a deal with Mission's Alamo Pharma Services subsidiary to commercialize the drugs, along with three drugs from Dara - Soltamox tamoxifen for breast cancer, Gelclair povidone for oral mucositis and Bionect 0.2% hyaluronic acid for burns and skin changes from radiation - in the U.S. by a 20-person, cancer sales team. In the first year of the deal, Dara will pay Alamo an undisclosed fee for the sales force, which is expected to be in the field by January 2014. In the second year and beyond, the partners will split profits. The companies declined to disclose details. ...